Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib

Micro-Abstract This analysis evaluated the protein synthesis inhibitor omacetaxine mepesuccinate (“omacetaxine”) in previously treated patients with chronic myeloid leukemia (CML). Patients with chronic-phase CML who had resistance or intolerance to 2 or more tyrosine kinase inhibitors were included (n = 81). Omacetaxine produced clinically meaningful responses with acceptable tolerability. These results support omacetaxine as a treatment option in this patient population.